《復牌公告》科倫博泰生物-B(06990.HK)擬申請內資股及非上市外資股轉換H股
科倫博泰生物-B(06990.HK)公布,董事會批准若干股東所持內資股及非上市外資股實施H股全流通。於取得所有相關批准,包括中國證監會的備案通知後,有關股份將轉換為H股,並向聯交所申請於聯交所主板上市及買賣。
有關H股全流通及上市的計劃詳情,尚需若干參與股東內部審批,公司尚未向中國證監會提交備案申請。
另外,公司收到默沙東的正式書面通知,其決定終止科倫博泰授予開發、製造和商業化一項臨床前ADC資產的獨家許可,及不行使獨家選擇權以獲得另一項臨床前ADC資產的獨家許可。公司與默沙東合作協議並無變動,三項臨床階段ADC資產及四項臨床前ADC資產的合作並未受到影響。
股份申請今日(24日)復牌。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.